Filing summary
Company and reporting date: bioAffinity Technologies, Inc. (Nasdaq: BIAF; warrants: BIAFW) filed this Form 8-K for an event dated September 30, 2026. The company identifies as an emerging growth company.
Business context and event
The company reported that it jointly exhibited CyPath® Lung for the first time under its recently announced distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business. The exhibition took place at the NAVREF Annual Conference in Arlington, Virginia, and was presented to more than 300 physicians, healthcare professionals, and VA leaders.
The filing does not describe product sales, orders, revenue, or other commercial outcomes from the exhibition. It refers to a September 30 press release, filed as Exhibit 99.1, but the press-release text is not included in the supplied filing content.
Financial results and comparison
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It provides no comparable-period results or financial guidance.
Outlook, risks, and unusual items
The filing announces a commercial-awareness event under the distribution agreement but gives no forecast, management outlook, stated risks, or contingencies related to the agreement or exhibition.
Important facts to verify
- Review Exhibit 99.1 for additional details about the exhibition and the distribution agreement.
- Verify whether the agreement leads to VA-related evaluations, orders, or commercial revenue; none are reported in this 8-K.
- Seek subsequent filings for financial results and any updates on CyPath® Lung commercialization.